title: Cyclin-dependent kinase 9 activity regulates neutrophil spontaneous apoptosis.
abstract: Neutrophils are the most abundant leukocyte and play a central role in the immune defense against rapidly dividing bacteria. However, they are also the shortest lived cell in the blood with a lifespan in the circulation of 5.4 days. The mechanisms underlying their short lifespan and spontaneous entry into apoptosis are poorly understood. Recently, the broad range cyclin-dependent kinase (CDK) inhibitor R-roscovitine was shown to increase neutrophil apoptosis, implicating CDKs in the regulation of neutrophil lifespan. To determine which CDKs were involved in regulating neutrophil lifespan we first examined CDK expression in human neutrophils and found that only three CDKs: CDK5, CDK7 and CDK9 were expressed in these cells. The use of CDK inhibitors with differing selectivity towards the various CDKs suggested that CDK9 activity regulates neutrophil lifespan. Furthermore CDK9 activity and the expression of its activating partner cyclin T1 both declined as neutrophils aged and entered apoptosis spontaneously. CDK9 is a component of the P-TEFb complex involved in transcriptional regulation and its inhibition will preferentially affect proteins with short half-lives. Treatment of neutrophils with flavopiridol, a potent CDK9 inhibitor, increased apoptosis and caused a rapid decline in the level of the anti-apoptotic protein Mcl-1, whilst Bcl2A was unaffected. We propose that CDK9 activity is a key regulator of neutrophil lifespan, preventing apoptosis by maintaining levels of short lived anti-apoptotic proteins such as Mcl-1. Furthermore, as inappropriate inhibition of neutrophil apoptosis contributes to chronic inflammatory diseases such as Rheumatoid Arthritis, CDK9 represents a novel therapeutic target in such diseases.
authors.affiliation: MRC Centre for Immune Regulation, Institute of Biomedical Research, Birmingham University Medical School, Birmingham, United Kingdom.
authors.forename: Keqing
authors.initials: K
authors.lastname: Wang
authors.forename: Peter
authors.initials: P
authors.lastname: Hampson
authors.forename: Jon
authors.initials: J
authors.lastname: Hazeldine
authors.forename: Vladimir
authors.initials: V
authors.lastname: Krystof
authors.forename: Miroslav
authors.initials: M
authors.lastname: Strnad
authors.forename: Paul
authors.initials: P
authors.lastname: Pechan
authors.forename: Janet
authors.initials: J
authors.lastname: M
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D002478:Cells, Cultured; D051360:Cyclin-Dependent Kinase 5 / Q000037:antagonists & inhibitors / Q000378:metabolism; D042863:Cyclin-Dependent Kinase 9 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D005419:Flavonoids / Q000494:pharmacology; D006801:Humans; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D009504:Neutrophils / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism*; D010880:Piperidines / Q000494:pharmacology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D011687:Purines / Q000494:pharmacology; D000077546:Roscovitine; D000095043:Cyclin-Dependent Kinase-Activating Kinase
chemical_list: D005419:Flavonoids; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D010880:Piperidines; D019253:Proto-Oncogene Proteins c-bcl-2; D011687:Purines; D000077546:Roscovitine; C077990:alvocidib; D051360:Cyclin-Dependent Kinase 5; C495905:CDK5 protein, human; D042863:Cyclin-Dependent Kinase 9; D018844:Cyclin-Dependent Kinases; D000095043:Cyclin-Dependent Kinase-Activating Kinase; C000722416:CDK7 protein, human